By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – XDx today said that Aetna has determined that the firm's AlloMap test is medically necessary for monitoring rejection in heart transplant recipients more than a year after a heart transplant.
Registering provides access to this and other free content.
Already have an account?Login Now.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.